Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR.

Nat Med. 2007 Sep;13(9):1032-4. Epub 2007 Aug 26.

2.

Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.

Wu L, Yang ZY, Xu L, Welcher B, Winfrey S, Shao Y, Mascola JR, Nabel GJ.

Vaccine. 2006 Jun 5;24(23):4995-5002. Epub 2006 Apr 18.

PMID:
16690178
3.

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.

Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA, Gorgone DA, Beaudry KR, Svehla K, Welcher B, Chakrabarti BK, Huang Y, Yang ZY, Mascola JR, Nabel GJ, Letvin NL.

J Virol. 2005 May;79(10):6516-22.

4.

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.

Chakrabarti BK, Ling X, Yang ZY, Montefiori DC, Panet A, Kong WP, Welcher B, Louder MK, Mascola JR, Nabel GJ.

Vaccine. 2005 May 16;23(26):3434-45.

PMID:
15837367
5.

Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B.

Roy CJ, Warfield KL, Welcher BC, Gonzales RF, Larsen T, Hanson J, David CS, Krakauer T, Bavari S.

Infect Immun. 2005 Apr;73(4):2452-60.

6.

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.

7.

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.

Yang ZY, Chakrabarti BK, Xu L, Welcher B, Kong WP, Leung K, Panet A, Mascola JR, Nabel GJ.

J Virol. 2004 Apr;78(8):4029-36. Erratum in: J Virol. 2006 Apr;80(8):4206.

8.

[Professionalism in psychiatry is essential--support to a contribution by professors in psychiatry].

Andersen HS, Anderson JE, Bendsen BB, Brinck T, Bundgaard E, Dam OH, Glenthoj B, Handest P, Hertz M, Jansson L, Jepsen PW, Jørgensen MB, Klysner R, Larsen A, Larsen JK, Lublin H, Middelboe T, Mikkelsen LB, Pedersen L, Sestoft D, Silberman L, Solstad K, Suenson M, Strømsø N, Ulrichsen J, Wedervang M, Welcher B.

Ugeskr Laeger. 2004 Jan 5;166(1-2):69-70. Danish. No abstract available.

PMID:
14752998
9.

Ebola virus-like particles protect from lethal Ebola virus infection.

Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15889-94. Epub 2003 Dec 12.

10.

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL.

J Virol. 2003 Oct;77(19):10348-56.

11.

Mutational effects on protein folding stability and antigenicity: the case of streptococcal pyrogenic exotoxin A.

Carra JH, Welcher BC, Schokman RD, David CS, Bavari S.

Clin Immunol. 2003 Jul;108(1):60-8.

PMID:
12865072
12.

Lethal shock induced by streptococcal pyrogenic exotoxin A in mice transgenic for human leukocyte antigen-DQ8 and human CD4 receptors: implications for development of vaccines and therapeutics.

Welcher BC, Carra JH, DaSilva L, Hanson J, David CS, Aman MJ, Bavari S.

J Infect Dis. 2002 Aug 15;186(4):501-10. Epub 2002 Jul 19.

PMID:
12195377
13.

Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines.

DaSilva L, Welcher BC, Ulrich RG, Aman MJ, David CS, Bavari S.

J Infect Dis. 2002 Jun 15;185(12):1754-60. Epub 2002 May 23.

PMID:
12085321
14.

The iceberg tip and the rest. Mental health care for people with schizophrenia in five European centres.

Becker T, Gaite L, Knapp M, Knudsen C, Leese M, Ruggeri M, Schene A, Tansella M, Thornicroft G, Vázquez-Barquero JL, Welcher B, Van Wijngaarden B.

Epidemiol Psichiatr Soc. 2002 Jan-Mar;11(1):6-11. No abstract available.

PMID:
12043434
15.

Quality of life in patients with schizophrenia in five European countries: the EPSILON study.

Gaite L, Vázquez-Barquero JL, Borra C, Ballesteros J, Schene A, Welcher B, Thornicroft G, Becker T, Ruggeri M, Herrán A; EPSILON Study Group.

Acta Psychiatr Scand. 2002 Apr;105(4):283-92.

PMID:
11942933
16.

Quality of life in schizophrenia: development, reliability and internal consistency of the Lancashire Quality of Life Profile--European Version. EPSILON Study 8. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs.

Gaite L, Vázquez-Barquero JL, Arrizabalaga Arrizabalaga A, Schene AH, Welcher B, Thornicroft G, Ruggeri M, Vázquez-Bourgon E, Pérez Retuerto M, Leese M.

Br J Psychiatry Suppl. 2000;(39):s49-54.

PMID:
10945078
17.

Translation and cross-cultural adaptation of outcome measurements for schizophrenia. EPSILON Study 2. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs.

Knudsen HC, Vázquez-Barquero JL, Welcher B, Gaite L, Becker T, Chisholm D, Ruggeri M, Schene AH, Thornicroft G.

Br J Psychiatry Suppl. 2000;(39):s8-14.

PMID:
10945072
18.

Admission of self-poisoned patients during one year at the Poisoning Treatment Centre, Copenhagen, Denmark.

Welcher B, Rubin P, Nordentoft M.

Acta Psychiatr Scand Suppl. 1993;371:38-44.

PMID:
8517182

Supplemental Content

Loading ...
Support Center